EYPT EyePoint (EYPT) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0001314102
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
90
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $40.3K priced
What the filings say about EYPT
Insiders, 180 days
-$20.9K net sold
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
EyePoint insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, EyePoint, Inc. insiders sold a net $20.9K of stock across 98 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 19, 2025.
- +85.7% median (+71.8% mean) 90-day return after 5 previous buys.
- The trade is 21.6% of the 49,100 shares held after it.
- No other insider bought within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Zaderej Karen L. bought about $52.3K of EYPT on Aug 18, 2026, the largest insider purchase at the company since 2024; 90 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Apr 17, 2026.
- The trade is 100.0% of the 2,438 shares held after it.
- No other insider sold within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Ribeiro Ramiro sold about $36.6K of EYPT on Jun 30, 2026; 90 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Apr 17, 2026.
- No other insider sold within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Ribeiro Ramiro sold about $36.6K of EYPT on Jun 30, 2026; 90 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 4, 2026.
- No other insider sold within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Ribeiro Ramiro sold about $36.6K of EYPT on Apr 17, 2026; 90 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1.5% of the 100,665 shares held after it.
- No other insider bought within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Duker Jay S. bought about $19.7K of EYPT on Mar 16, 2026; 90 funds added in the latest 13F quarter.98 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$20.9K over 180 days
+$52.3K over 90 days
more than 60% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
90 funds bought in last quarter
more than 62% of Medical Devices
Revenue
-27.5% year over year
below 91% of Medical Devices
Margin
-739.4% net margin
below 95% of Medical Devices
Buybacks
no share repurchases reported
Short interest
34.3% of the float short (float per yahoo 2026-10-26) · 5.4 days to cover · settled 2026-09-30
more than 99% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch EYPT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-96.8%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns EYPT: institutional holders (13F)
13F holdings, latest reported quarter
8,296,375 sh
$118.6M
7,463,197 sh
$106.7M
7,000,000 sh
$100.1M
5,681,052 sh
$81.2M
4,827,792 sh
$69.0M
Congress trades in EYPT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
EYPT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Lurker Nancy
Filed 2026-07-21
$5.5M
EYPT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$7.6M position · as of 2026-06-30
1.8%
PROFUND VP PHARMACEUTICALS
$197.7K position · as of 2026-06-30
1.7%
Simplify Health Care ETF
$5.2M position · as of 2026-06-30
1.4%
Franklin Biotechnology Discovery Fund
$13.8M position · as of 2026-07-31
1.2%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$233.4K position · as of 2026-07-31
1.1%
Eventide Healthcare & Life Sciences Fund
$17.8M position · as of 2026-06-30
1.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Jay Duker
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.6M
$14.0M
$2.2M
+422%
n/a
2024
$6.0M
-$3.6M
$3.3M
+113%
n/a
2022
$3.4M
$330.2K
$1.8M
-71%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $20.9K sold by insiders over 180 days, 90 funds added last quarter. Each figure is a federal filing, dated the day it went public.
EYPT financials
Revenue growth
-27.5%
XBRL, annual
Net margin
-739.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM EYPT
| FY Dec 2025 | $31.4M |
| FY Dec 2024 | $43.3M |
| FY Dec 2023 | $46.0M |
| FY Dec 2022 | $41.4M |
| FY Dec 2021 | $36.9M |
| Jun 2026 | $507.0K |
| Mar 2026 | $696.0K |
| Dec 2025 | $620.0K |
| Sep 2025 | $966.0K |
| Jun 2025 | $5.3M |
| Mar 2025 | $24.5M |
| Dec 2024 | $11.6M |
| Sep 2024 | $10.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-10,995%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM EYPT
| FY Dec 2025 | -739.4% |
| FY Dec 2024 | -302.4% |
| FY Dec 2023 | -153.8% |
| FY Dec 2022 | -247.0% |
| FY Dec 2021 | -158.1% |
| Jun 2026 | -18,633% |
| Mar 2026 | -12,189% |
| Dec 2025 | -10,905% |
| Sep 2025 | -6,183% |
| Jun 2025 | -1,114% |
| Mar 2025 | -184.8% |
| Dec 2024 | -357.3% |
| Sep 2024 | -279.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$271.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM EYPT
| FY Dec 2025 | -$243.4M |
| FY Dec 2024 | -$130.3M |
| FY Dec 2023 | -$1.6M |
| FY Dec 2022 | -$67.2M |
| FY Dec 2021 | -$50.3M |
| Jun 2026 | -$63.5M |
| Mar 2026 | -$81.5M |
| Dec 2025 | -$66.0M |
| Sep 2025 | -$60.2M |
| Jun 2025 | -$63.8M |
| Mar 2025 | -$53.4M |
| Dec 2024 | -$36.2M |
| Sep 2024 | -$40.6M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2023-09-30 (33 months older than the period end) plus current 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity EYPT
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.41x |
| FY Dec 2021 | 0.20x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt EYPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1.63x |
| FY Dec 2021 | -1.37x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-148.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity EYPT
| FY Dec 2025 | -72.2% |
| FY Dec 2024 | -43.4% |
| FY Dec 2023 | -39.0% |
| FY Dec 2022 | -72.8% |
| FY Dec 2021 | -57.6% |
| Jun 2026 | -148.7% |
| Mar 2026 | -102.7% |
| Dec 2025 | -72.2% |
| Sep 2025 | -98.2% |
| Jun 2025 | -74.0% |
| Mar 2025 | -53.5% |
| Dec 2024 | -43.4% |
| Sep 2024 | -74.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-115.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets EYPT
| FY Dec 2025 | -59.3% |
| FY Dec 2024 | -33.8% |
| FY Dec 2023 | -26.4% |
| FY Dec 2022 | -46.1% |
| FY Dec 2021 | -32.9% |
| Jun 2026 | -115.9% |
| Mar 2026 | -83.5% |
| Dec 2025 | -59.3% |
| Sep 2025 | -74.5% |
| Jun 2025 | -56.1% |
| Mar 2025 | -42.4% |
| Dec 2024 | -33.8% |
| Sep 2024 | -44.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital EYPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-139.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed EYPT
| FY Dec 2025 | -69.9% |
| FY Dec 2024 | -44.1% |
| FY Dec 2023 | -34.3% |
| FY Dec 2022 | -51.7% |
| FY Dec 2021 | -34.9% |
| Jun 2026 | -139.6% |
| Mar 2026 | -98.6% |
| Dec 2025 | -69.9% |
| Sep 2025 | -92.2% |
| Jun 2025 | -71.3% |
| Mar 2025 | -54.9% |
| Dec 2024 | -44.1% |
| Sep 2024 | -67.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing EYPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$78.6M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2023-09-30 (33 months older than the period end) plus current 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value EYPT
| FY Dec 2025 | $1.4B |
| FY Dec 2024 | $408.8M |
| FY Dec 2023 | $534.7M |
| FY Dec 2022 | $63.4M |
| FY Dec 2021 | $210.1M |
| Jun 2026 | $1.1B |
| Mar 2026 | $997.7M |
| Dec 2025 | $1.4B |
| Sep 2025 | $906.9M |
| Jun 2025 | $576.4M |
| Mar 2025 | $287.4M |
| Dec 2024 | $408.8M |
| Sep 2024 | $347.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-850.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield EYPT
| FY Dec 2025 | -16.1% |
| FY Dec 2024 | -25.6% |
| FY Dec 2023 | -0.2% |
| FY Dec 2022 | -56.3% |
| FY Dec 2021 | -14.3% |
| Jun 2026 | -22.6% |
| Mar 2026 | -25.2% |
| Dec 2025 | -16.1% |
| Sep 2025 | -21.8% |
| Jun 2025 | -30.0% |
| Mar 2025 | -40.6% |
| Dec 2024 | -25.6% |
| Sep 2024 | -27.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing EYPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M |
| Operating income | -$243.4M | -$145.9M | -$75.1M | -$99.6M |
| Net income | -$232.0M | -$130.9M | -$70.8M | -$102.3M |
| EPS (diluted) | -3.17 | -2.32 | -1.82 | -2.74 |
| Operating cash flow | -$240.1M | -$126.2M | $1.9M | -$65.0M |
| Cash | $101.8M | $99.7M | $281.3M | $95.6M |
| Long-term debt | n/a | n/a | n/a | $29.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
EYPT Stock Sonar score 6/7 axes
Find similar shapesCompareEYPT ranks highest on financial health (99th percentile) and institutional and government (62nd), and lowest on growth (9th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
EYPT filings, in plain words
Are EyePoint insiders buying or selling EYPT?
In the 180 days to 2026-10-28, EyePoint insiders were net sellers, a net $20.9K: $52.3K of purchases and $73.2K of sales reported on Form 4, by 1 buyer and 1 seller.
Read the full summary
In the 180 days to 2026-10-28, EyePoint insiders were net sellers of EYPT, a net $20.9K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
